Document text
Principal Investigator: Luis J Montaner
Organization: WISTAR INSTITUTE
Fiscal Year: 2021
Award: $156,933
Funding agency: National Institute on Drug Abuse
SUMMARY
The administration of effective anti- SARS-CoV-2 vaccines capable of eliciting a protective immune response in
a large proportion of the population is a major public heath priority in combating Coronavirus disease 2019
(COVID-19). Our studies indicates that the functionality of soluble antibodies (i.e.: humoral immunity) is affected
by chronic inflammation, such as chronic HIV infection and/or opioid use. Our short-term objective is to evaluate
the quality and persistence of anti-SARS-CoV-2 antibody response in people living with HIV (PLWH) a) receiving
a SARS-CoV-2 vaccination, b) on treatment with suppressive antiretroviral therapy (ART) and c) on treatment
with mu opioid receptor (MOR) agonists methadone or buprenorphine for opioid use disorder (OUD). Based on
the literature and our pilot studies, our primary hypothesis is that in ART-treated PLWH receiving MOR
agonists-based treatment and SARS-CoV-2 vaccination will result in shorter retention of neutralizing titers and
with different qualitative antibody responses [including lower antibody-dependent cell cytotoxicity
(ADCC)/antibody-dependent cell phagocytosis (ADCP)] when compared to vaccine responses in ART
suppressed PLWH who do not use opioids. To address this hypothesis, we will study a cohort of 90 PLWH
receiving suppressive ART (VL < 50 c/ml) at approximately 4, 8 and 12 months from SARS-CoV-2 vaccination,
in the following groups: (1) OUD on methadone, (2) OUD on buprenorphine/naloxone (Suboxone), and (3) ART-
only non-OUD control. We will test our hypothesis by completion of the following aims:
Specific Aim 1. To quantify functional anti-SARS-CoV-2 antibody responses by measuring: (a) SARS-CoV-2
antibody response by total binding antibody to Spike protein, and titers of neutralizing antibody against of Vero
cells infected with wildtype SarsCoV2 (WA1/2020-Wuhan) or variants of concern (B.1.1.7-UK, or B.1.351-South
Africa); (b) Anti-SARS-CoV-2 antibody activity in recruiting innate immune functions by complement deposition
(ADCD), phagocytosis (ADCP), and cytotoxicity (ADCC).
Specific Aim 2. To evaluate the relationships between SARS-CoV-2 antibody responses, immune activation
and HIV latency by measuring: (a) Microbial translocation and mucosal integrity by assessing plasma markers
of bacterial translocation (e.g.: sCD14, sCD163, LPS, EndoCAB), and mucosal structural integrity (e.g.: Intestinal
fatty acid-binding protein (I-FABP) and Zonulin-1); (b) Levels of cell-associated HIV DNA (intact and total), HIV
RNA (different transcript), and HIV transcriptional activity (ratio of HIVDNA/HIV RNA. The successful completion
of this study will provide novel insights on the ability of ART-suppressed PLWH receiving treatment with MOR
agonists to fully benefit from SARS-CoV-2 vaccinations.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><AIDS Virus><Ab-dependent cellular cytotoxicity><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Adanon><Address><Affect><Agonist><Althose><Antibodies><Antibody Response><Antibody titer measurement><Antiviral Agents><Antiviral Drugs><Antivirals><Award><B.1.1.7><B.1.351><Bacterial Translocation><Binding><Blood Plasma><Blood Sample><Blood specimen><Bunavail><Buprenorphine><CD14><CD14 gene><COVID infected patient><COVID patient><COVID positive patient><COVID-19><COVID-19 antibody><COVID-19 infected patient><COVID-19 patient><COVID-19 positive patient><COVID-19 vaccination><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 patient><COVID19 positive patient><COVID19 vaccination><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cell Body><Cells><Chronic><CoV-2><CoV2><Complement><Complement Proteins><DNA><Data><Deoxyribonucleic Acid><Deposit><Deposition><Development><Dolophine><Drugs><Gene Transcription><Genetic Transcription><HIV><HIV Infections><HIV anti-retroviral><HIV antiretroviral><HIV-1><HIV-I><HIV1><HTLV-III Infections><HTLV-III-LAV Infections><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Infections><Human immunodeficiency virus 1><Humoral Immunities><Immune><Immune Cell Activation><Immune mediated therapy><Immune response><Immunes><Immunological response><Immunologically Directed Therapy><Immunotherapy><Individual><Infection><Inflammation><LAV-HTLV-III><Literature><Lymphadenopathy-Associated Virus><Lytotoxicity><Measures><Medication><Methadone><Methadose><Molecular Interaction><Mucosa><Mucosal Tissue><Mucous Membrane><Myelogenous><Myeloid><Non-Polyadenylated RNA><Opiate Receptors><Opiate agonist><Opiate receptor agonist><Opioid Receptor><Opioid agonist><Opioid receptor agonist><Parents><Patients><Persons><Phagocytosis><Pharmaceutic Preparations><Pharmaceutical Preparations><Philadelphia><Pilot Projects><Plasma><Plasma Serum><Population><Proteins><RNA><RNA Expression><RNA Gene Products><RNA vaccine><RNA-based vaccine><Recovery><Reticuloendothelial System, Serum, Plasma><Ribonucleic Acid><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 B.1.1.7><SARS-CoV-2 B.1.351><SARS-CoV-2 antibody><SARS-CoV-2 infected patient><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 antibody><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><South Africa><South Africa variant><South African variant><Structure><Suboxone><Testing><Time><Transcript><Transcription><U.K. variant><UK variant><United Kingdom variant><Vaccination><Vaccines><Vero Cells><Viral reservoir><Virus reservoir><Virus-HIV><Wuhan coronavirus><Zubsolv><anti-retroviral therapy><anti-retroviral treatment><anti-viral agents><anti-viral drugs><anti-virals><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody dependent cell mediated cytotoxicity><antibody dependent cytotoxicity><antibody titering><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><antibody-based immunity><antibody-dependent cell cytotoxicity><antibody-dependent cellular cytotoxicity><antibody-mediated cytotoxicity><antiretroviral therapy><antiretroviral treatment><base><buprenorphine + naloxone><buprenorphine and naloxone><buprenorphine with naloxone><buprenorphine-naloxone><buprenorphine/naloxone><cohort><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 infected patient><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus patient><cytotoxicity><developmental><disease control><disorder control><drug/agent><hCoV19><host response><immune activation><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunoresponse><innate immune function><insight><intestinal fatty acid binding protein><licit opioid><mRNA vaccine><mRNA-based vaccine><medication-assisted treatment><microbial><mu opioid receptors><nCoV2><neutralizing antibody><non-narcotic analgesic><non-opiate analgesic><non-opioid><non-opioid analgesic><non-opioid therapeutics><nonnarcotic analgesics><nonopiate analgesic><nonopioid><nonopioid analgesics><novel><opiate consumption><opiate drug use><opiate intake><opiate medication><opiate use><opiate use disorder><opioid consumption><opioid drug use><opioid intake><opioid medication><opioid use><opioid use disorder><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient population><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><pilot study><prescribed opiate><prescribed opioid><prescription opiate><prescription opioid><recruit><response><severe acute respiratory syndrome coronavirus 2 B.1.1.7><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><vaccinate against COVID-19><vaccinate against COVID19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination against COVID-19><vaccination against COVID19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><vaccine response><variants of concern><zonulin><μ opioid receptors><μ-OR><μOR>